Medpace Holdings, Inc. Reports Second Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Medpace (MEDP) PT Raised to $31 at Jefferies; Remains Sidelined
August 2, 2017 8:59 AM EDTJefferies raised its price target on Medpace (NASDAQ: MEDP) to $31.00 (from $30.00) while maintaining a Hold rating. Bad debt was reduced/avoided, and bookings improved sequentially. EBITDA guidance post 1Q17 ($106-108M) included $2-3M of bad debt exposure expected to hit the... More
